Expert consensus on precise diagnosis and management of primary hepatocellular carcinoma in advanced stage (2023 version).
10.3760/cma.j.cn501113-20230717-00006
- VernacularTitle:晚期原发性肝癌精细化诊疗管理专家共识（2023年版）
- Collective Name:National Clinical Research Center for Infectious Diseases;Society of Hepatology, Beijing Medical Association;Translational Medicine Branch, China Association of Gerontology and Geriatrics
- Publication Type:Journal Article
- Keywords:
Expert consensus;
Hepatocellular carcinoma;
Immunotherapy;
Precise management;
Targeted therapy
- MeSH:
Humans;
Carcinoma, Hepatocellular/pathology*;
Liver Neoplasms/pathology*;
Consensus;
Prognosis;
China
- From:
Chinese Journal of Hepatology
2023;31(9):910-920
- CountryChina
- Language:Chinese
-
Abstract:
not matching with chinese abstract stage in China. By adopting the "Delphi" consensus formation method, a set of precise staging criteria and corresponding preferred treatment protocols were agreed upon for Chinese patients with hepatocellular carcinoma in advanced stage, taking into account different tumor characteristics, vascular embolism grading, distant metastasis and liver function status, portal hypertension, hepatitis B virus replication status, etc., as well as the prognosis of the patients. This consensus is intended to provide a more detailed, scientific, and reasonable reference basis for the selection of individualized diagnosis and treatment plans for frontline clinicians.
